Citizens cuts Zimmer Biomet stock price target on mixed results By Investing.com

Zimmer Biomet reported Q1 2026 EPS of $2.09, about 12% above the $1.87 consensus, on revenue of $2.09 billion versus $2.06 billion expected. The beat was boosted by an approximately $0.20 benefit from invalidated IEEPA tariffs, and the company raised full-year bottom-line guidance by $0.10 at the midpoint while reaffirming revenue growth of 2.5% to 4.5% reported and 2.0% to 4.0% organic. Analyst targets were trimmed, but the stock remains near its 52-week low.

Analysis

The cleanest read is that this is less a true operating inflection than a margin event that pulled forward earnings. A tariff refund can temporarily mask weak-to-mid single-digit organic growth, and that matters because the market tends to re-rate medtech on durable procedure growth, not one-time gross margin help. The knee underperformance is the important tell: if the largest franchise is not accelerating, then the current multiple reset may be justified unless pricing or utilization improves over the next 2-3 quarters.

Second-order, the beat may actually intensify scrutiny on the rest of the medtech complex. Peers with cleaner organic comp but less near-term tariff benefit could look better on a normalized basis, especially if investors start stripping out transitory tax and tariff items from earnings power. That creates a window where the “quality growth” names in orthopedics and adjacent procedure-driven devices can outperform ZBH even if absolute results are less dramatic.

The contrarian angle is that the stock may be oversold relative to normalized earnings power, but not necessarily cheap on forward fundamentals if the tariff tailwind is excluded. The market is likely underestimating how much of the current guidance confidence depends on reimbursement/procedure stability into the second half. If volumes soften or the tariff benefit proves less repeatable, the recent multiple lift should fade quickly over the next 1-2 reporting cycles.

Key Decisions for Investors

• Long ZBH only as a tactical trade into sentiment repair, not a core hold: buy on weakness near the low-$80s with a 1-2 quarter horizon; target a move back toward the low/mid-$90s if investors re-rate normalized EPS, but cut if organic growth fails to re-accelerate next print.
• Pair trade: long a higher-quality orthopedics/medical device peer with cleaner organic growth versus short ZBH for 6-12 weeks; the thesis is that the market will reward durable procedure growth and penalize tariff-driven EPS quality.
• Sell upside calls against any ZBH long exposure for the next earnings cycle; implied upside can be harvested because the stock’s rerating is constrained unless knees and broader organic growth improve.
• For event-driven accounts, wait for the next guide revision or procedure-volume data before adding materially; the near-term catalyst is less the beat itself than whether management can demonstrate that second-half numbers are not being propped up by one-offs.
• If you want to express the contrarian view, use a small starter long with a defined stop below the 52-week low rather than outright size; the risk/reward is asymmetric only if the market decides to capitalize normalized earnings instead of headline EPS.